Similar Articles |
|
Chemistry World April 25, 2008 Rebecca Trager |
Environmental Scientists Report Political Interference Hundreds of the US Environmental Protection Agency's scientific staff have experienced political interference in their work, a survey has revealed. |
Pharmaceutical Executive January 1, 2009 Jill Wechsler |
FDA Turnaround Time Will more resources and new leadership fix FDA, or is a major overhaul in order? |
Chemistry World August 7, 2015 Rebecca Trager |
US research agencies accused of stifling communication of science US government agencies have put in place obstacles that thwart efforts by science journalists to effectively communicate government science, according to a new report from the Union of Concerned Scientists. |
Chemistry World March 6, 2014 Rebecca Trager |
Politicians accuse US food agency of illegally monitoring employees Republican leaders on two key congressional committees have concluded in a new report that the US Food and Drug Administration illegally monitored email communications sent by whistleblowers in the agency. |
Geotimes May 2006 Constantine & Wilkinson |
Translating Science Into Informed Policies To discuss how to get more scientific integrity into policy-making, graduate students at the University of California in Santa Barbara held a panel discussion with the hopes of raising awareness about political interference in government science. |
Pharmaceutical Executive October 1, 2006 Patrick Clinton |
From the Editor: In Conflict Structured conflicts keep the pharmaceutical industry functioning, and threatens it when they get out of balance. |
Chemistry World February 3, 2012 Rebecca Trager |
Whistleblowers accuse FDA of spying, persecution The US Food and Drug Administration is being sued by its own scientists and doctors who allege they were spied on and persecuted by the agency for expressing safety concerns about the approval of medical devices. |
Pharmaceutical Executive September 1, 2006 Jill Wechsler |
Pharm Exec Q&A: A Soft Spot for Whistleblowers FDA's most aggressive critic in Washington is Iowa Senator Charles Grassley. In this exclusive interview, he explains where the agency goes wrong and what he would do to fix it. |
Pharmaceutical Executive June 1, 2012 Jill Wechsler |
Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market. |
Pharmaceutical Executive January 1, 2007 |
Thoughtleader: Peter Pitts. DrugWonks.com Here, the chief voice of a blog hosted by the non-profit Center for Medicine in the Public Interest urges pharma to continuously plug its positions and get politics out of science, and offers some perspective on important regulatory reforms facing the FDA. |
The Motley Fool December 5, 2007 Brian Lawler |
The FDA Says It Needs a Pep Pill Drugmakers offering new treatments might be discouraged by the FDA's latest report, in which the agency makes its case for additional funding from Congress. |
Pharmaceutical Executive June 1, 2007 Clinton & Wechsler |
The View From Inside Commissioner Andrew von Eschenbach on drug safety, DTC advertising, FDA's culture, and how the agency plans to bring itself into the age of molecular medicine. |
Chemistry World February 16, 2015 Patrick Walter |
Poll finds majority of scientists engaging with public Scientists believe that they should take an active role in public policy debates when it comes to science and technology, according to a survey of American Association for the Advancement of Science members. |
Pharmaceutical Executive September 1, 2005 Jill Wechsler |
Washington Report: Crawford Steps Up As FDA's new commissioner takes the reins, his key challenge is restoring trust in the agency. |
Science News May 9, 2009 Charles Niederriter |
At Nobel Conference, Scientists And Public Converse The author, a physics professor at Gustavus Adolphus College directs the Nobel Conference, an annual forum where scientists and the public discuss a contemporary scientific topic. |
Chemistry World October 22, 2014 Rebecca Trager |
Free legal help for embattled US scientists A pro bono network that will provide legal protection for US scientists in government and academia has been launched by the Public Employees for Environmental Responsibility, an environmental group based in Washington, DC. |
The Motley Fool March 31, 2008 Brian Lawler |
FDA Commish Joins Blogosphere Andrew von Eschenbach, the FDA's chief, starts a weekly blog. |
Pharmaceutical Executive April 1, 2007 Patrick Clinton |
From the Editor: Taking It Outside FDA Commissioner Andy von Eschenbach said something pretty reasonable, and in return received a blistering, menacing letter from Senator Charles Grassley -- a letter that showed yet again that Grassley just doesn't understand what he's destroying in his campaign against FDA. |
CIO March 15, 2006 Allan Holmes |
Rx for Risk As it revamps its workflow processes, the FDA is relying on technology to reduce the risk that unsafe substances will get into the market. |
Information Today July 28, 2015 |
Pew Report Delves Into Scientific Attitudes The report, "An Elaboration of AAAS Scientists' Views," explores findings by examining American Association for the Advancement of Science scientists' views on major science-related issues. |
Reason November 2005 Tim Cavanaugh |
Subsidized Spin The Pentagon is spending $300,000 to send mid-career scientists, researchers, and engineers to a workshop at the television and screen writing school with the hope that some of these scientists will be inspired to produce a screenplay that paints scientists as cool. |
Pharmaceutical Executive April 1, 2006 Jill Wechsler |
Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf? |
Pharmaceutical Executive February 1, 2012 Jennifer Ringler |
Industry Trees are Falling, But is FDA Around to Hear? Experts weigh in on FDA's long-awaited social media guidelines. |
The Motley Fool September 29, 2011 Brian Orelli |
Investors Guide to the New PDUFA Changes are in the air for drugmakers and the FDA. |
Geotimes July 2004 |
Suppressing Science in Policy: Sharing Responsibility Recent publicity of the use of science in policy offers an opportune platform from which to reflect not only on the issues raised by politicians and UCS, but also on scientists' own role in widening the gap between science and policy. |
Geotimes May 2006 Steven Quane |
The Rocket Docket: Legislating Science Out of Public Policy Rhetorically, little resistance exists for U.S. policy-makers to use science fairly and justly in creating the laws of the land. Procedurally, however, that is certainly not the case. |
The Motley Fool April 29, 2008 Brian Orelli |
Will These Drugs Get FDA Approval? Discovery Laboratories and Adolor are waiting FDA decisions on their drugs next month. |
Chemistry World January 3, 2013 Sile Lane |
Decisive uncertainty We depend on scientists, often at fraught moments where lives are at stake, being willing to assess the evidence and speak the truth to those in power, as they see it, with all the uncertainties and in the context of what has gone before. |
Chemistry World May 2007 |
Comment: A Matter of Ethics Scientists should embrace a universal ethical code. |
Pharmaceutical Executive December 1, 2011 Jill Wechsler |
FDA Gets a New Look Agency expansion and globalization promote innovation, collaboration, and organizational changes |
Pharmaceutical Executive April 1, 2007 McCook & Daniels |
Making the Switch More companies are using Rx-to-OTC switches to extend a brand's life cycle. Prilosec did it. Here, experts dish on how you can do it too. |
Chemistry World September 6, 2012 Simon Perks |
Rebuilding public trust in Japanese science The aftermath of the Japanese earthquake, the ensuing tsunami and the Fukushima nuclear accident has destroyed the country's trust in science and its role in policy-making. |
The Motley Fool April 1, 2011 Travis Hoium |
Optimer Pharmaceuticals Shares Popped: What You Need to Know Shares of Optimer Pharmaceuticals jumped 12% today after positive news from the FDA was released. |
Reason April 2004 Todd Seavey |
Regulation for Dummies A book about the FDA. |
Pharmaceutical Executive February 1, 2011 Jill Wechsler |
Challenges, Changes, Commitments The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency |
The Motley Fool September 9, 2010 Brian Orelli |
Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September. |
Food Processing January 2005 David Joy |
Regulatory Issues: The FDA agenda for 2005 As in the past, the FDA has a full agenda of food regulatory matters in 2005. So it's not good that the FDA's scientists are demoralized and the agency stands accused of being too friendly with a regulated industry. |
Pharmaceutical Executive October 1, 2011 Ansis Helmanis |
Lessons from the FDA Front Line Is the research-based industry less productive today than 30 years ago? To former Commissioner Jane Henney, the answer is straightforward. |
The Motley Fool October 19, 2010 Brian Orelli |
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. |
IndustryWeek October 19, 2011 |
FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies? |
Pharmaceutical Executive April 1, 2009 Patrick Clinton |
Dear Commissioner... Unsolicited advice for FDA's next leader: Keep it real, fight popular delusions, and somehow, please, defend the agency. |
Chemistry World January 3, 2013 Steve Fuller |
The public: clients of science? Despite the lip service paid to the virtues of secular democracy, the extent to which the public trusts blindly in research scientists rivals medieval deference to priestly authority. |
Pharmaceutical Executive March 1, 2012 Jill Wechsler |
When Talk is Not So Cheap FDA and industry are pushing user fees, while they struggle with curbs on communications. |
Reason May 2005 Ronald Bailey |
Aborting Plan B Barr Pharmaceuticals wants to offer its emergency contraceptive levonorgestrel, marketed as Plan B, over the counter rather than by prescription. The FDA delayed an anticipated decision on the issue indefinitely, adding another chapter to a long and heavily politicized debate. |
Chemistry World September 5, 2013 Rebecca Trager |
Funding woes lead US scientists to consider moving overseas A new report paints a bleak picture of scientists conducting government funded research in the US. As many as 18% of US scientists questioned for the analysis are considering taking their research to another country. |
Entrepreneur March 2005 Stephen Barlas |
Just the facts The FDA doesn't want any more lies on dietary supplement labels... Is Sarbanes-Oxley a Class Act?... etc. |
Chemistry World June 4, 2009 Rebecca Trager |
US regulator rethink on BPA The US Food and Drug Administration (FDA) is revisiting its stance that bisphenol A is safe at current exposure levels. |
The Motley Fool May 9, 2007 Brian Lawler |
Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note. |
Pharmaceutical Executive March 1, 2012 Ron Cohen |
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership. |
Chemistry World January 21, 2010 Rebecca Renner |
FDA shifts on BPA safety The US Food and Drug Administration has revised its position on the possible developmental health risks from bisphenol A, the controversial and widely used ingredient in hard plastic bottles and food packaging that it declared safe in 2008. |